Key Differences Between Auvelity and Long-Acting Bupropion
Auvelity is fundamentally different from long-acting bupropion alone because it combines dextromethorphan (45 mg) with bupropion (105 mg) in a fixed-dose formulation that targets both glutamatergic and monoaminergic systems, resulting in faster antidepressant onset and potentially superior efficacy compared to bupropion monotherapy. 1
Mechanism of Action
Auvelity provides dual mechanisms:
- Dextromethorphan component: Acts as an uncompetitive NMDA receptor antagonist and sigma-1 receptor agonist, modulating glutamatergic neurotransmission 1
- Bupropion component: Functions both as a norepinephrine/dopamine reuptake inhibitor AND as a CYP2D6 inhibitor that increases dextromethorphan bioavailability by 20-32 fold at steady state 1
Long-acting bupropion alone only provides norepinephrine and dopamine reuptake inhibition without the glutamatergic modulation 2
Dosing and Pharmacokinetics
Auvelity:
- Fixed combination: 45 mg dextromethorphan/105 mg bupropion twice daily
- Steady state achieved within 8 days
- Dextromethorphan half-life extended to 22 hours (versus ~3-6 hours without bupropion) 1
- The bupropion dose (210 mg/day total) is lower than typical therapeutic doses
Long-acting bupropion:
- Standard dosing: 150-450 mg daily 3
- Typical therapeutic dose: 300 mg daily for depression 4
- No pharmacokinetic enhancement of other compounds
Clinical Efficacy
Auvelity demonstrates:
- Rapid onset: Significant improvement in Montgomery-Åsberg Depression Rating Scale (MADRS) scores within 1-2 weeks 5, 6
- Superior efficacy: Phase 2 trial showed Auvelity significantly outperformed bupropion monotherapy (at equivalent 105 mg twice daily dosing) 7, 5
- High remission rates: Long-term studies showed ~70% remission rates and >80% response rates 5
Bupropion monotherapy:
- Typical antidepressant onset: 4-8 weeks 2
- Standard efficacy comparable to other second-generation antidepressants 2
Side Effect Profile
Auvelity's most common adverse effects:
- Dizziness (unique to the combination, likely dextromethorphan-related)
- Headache
- Dry mouth
- Nausea 7, 5, 6
Bupropion alone:
- Lower rate of sexual dysfunction compared to SSRIs 2
- Seizure risk (~1 in 1000) 3, 4
- Insomnia
- Agitation
- No significant weight gain 2
Important Clinical Considerations
Shared contraindications (both contain bupropion):
- Seizure disorders or conditions lowering seizure threshold (brain metastases, stroke) 3
- Concurrent MAO inhibitor use 3
- Eating disorders 3
Auvelity-specific considerations:
- CYP2D6 poor metabolizers: Require dose adjustment due to higher dextromethorphan levels 1
- Drug interactions: More complex due to dextromethorphan component and strong CYP2D6 inhibition 8
- Cost and access: Significantly more expensive; no generic available 9
- Renal impairment: Dose adjustment needed for moderate impairment (eGFR 30-59); not recommended for severe impairment 1
Clinical Decision-Making Algorithm
Choose Auvelity when:
- Rapid antidepressant response is critical
- Patient has failed bupropion monotherapy at adequate doses
- Patient has treatment-resistant depression requiring novel mechanism
- Cost/insurance coverage is not prohibitive
Choose long-acting bupropion when:
- Cost is a significant concern
- Patient is CYP2D6 poor metabolizer (simpler dosing)
- Patient has multiple drug interactions (fewer concerns with bupropion alone)
- Standard antidepressant timeline is acceptable
- Patient specifically needs higher bupropion doses (300-450 mg) for smoking cessation or depression 3, 4
Critical caveat: The 105 mg twice daily bupropion dose in Auvelity (210 mg total daily) is lower than the typical 300-450 mg daily used for depression or smoking cessation 3, 7. Direct comparisons between Auvelity and higher-dose bupropion monotherapy have not been conducted, so the superior efficacy may reflect the dextromethorphan contribution rather than inadequate bupropion dosing in comparator arms 7.